Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
CD38 CAR Binder Structures and Affinity Tuning
2026-10-02
Cheng et al. define how the CD38-targeting binders RP02 and 028 engage different antigen surfaces, linking epitope geometry to enzymatic inhibition and CAR-T behavior. The study further shows that the affinity-attenuated 028R103G variant can reduce CAR-T fratricide while retaining cytotoxicity against CD38-positive tumor cells, providing a structure-guided framework for optimizing binder performance.
-
A 83-01: Selective ALK-5 Inhibitor Guide
2026-10-01
A 83-01 is a selective ALK-5 inhibitor that suppresses TGF-β/Smad signaling and supports epithelial-mesenchymal transition (EMT) research. Product-reported activity includes an approximately 12 nM IC50 and 68% inhibition of ALK-5-induced reporter activity at 1 μM in Mv1LuR4-2 cells.
-
Imipramine: A Smarter Autophagy Assay Strategy
2026-10-01
Imipramine is a tricyclic antidepressant with applications spanning glioma cell autophagy research, apoptosis assays, and neurobiology. This article develops a decision framework that connects the compound’s research profile with ceramide-driven autophagy findings while clearly separating evidence from testable hypotheses.
-
SB 431542 Workflow for ALK5 Inhibition
2026-09-30
SB 431542 provides a practical way to test ALK5-dependent TGF-β responses in cancer, immune, and stem/progenitor-cell assays. This workflow combines mechanism-based controls with the long-term myogenic engraftment framework reported in a 2025 human PSC study, while emphasizing dose selection, timing, and interpretation limits.
-
N4-Acetylcytidine: RNA Modification Workflows
2026-09-30
N4-Acetylcytidine supports controlled studies of free ac4C metabolism, post-transcriptional RNA modification, and enzyme substrate specificity. This guide separates RNA-embedded biology from free acetylated cytidine assays, with practical preparation, controls, troubleshooting, and structure-guided applications.
-
Human iPSC Sensory Neurons Model HSV-1 Latency
2026-09-29
Oh et al. developed a scalable human induced pluripotent stem cell system that rapidly produces functional sensory neurons and supports experimentally defined HSV-1 latency and reactivation. The model combines neuronal physiology with virological, transcriptional, and chromatin-based validation, offering a human-relevant platform for studying neuron-intrinsic mechanisms and testing latency-directed interventions.
-
TBXA2R–ERM Signaling in TNBC Metastasis
2026-09-29
The reference study identifies TBXA2R as a GPCR that activates ezrin, radixin, and moesin through Gαq/11, Gα12/13, Rho GTPases, and the kinases SLK and LOK. This signaling axis links receptor activity to triple-negative breast cancer cell motility, invasion, and metastatic colonization, establishing ERM function as a mechanistic requirement rather than a passive correlate.
-
Necrosulfonamide Workflows for MLKL Research
2026-09-28
Necrosulfonamide provides a selective way to test whether membrane-disruptive necroptosis, rather than apoptosis, drives a radiation response. This practical guide connects NSA handling and assay controls with carbon-ion cancer research, emphasizing interpretable workflows and troubleshooting.
-
A 83-01 ALK-5 Inhibitor for Kidney Fibrosis
2026-09-28
Use A 83-01 to test whether ALK-5-dependent TGF-β signaling contributes to fibroblast activation—not as a stand-in for Spp1 perturbation. This kidney-fibrosis workflow pairs carefully controlled inhibitor dosing with early Smad readouts and later myofibroblast markers, while flagging selectivity and vehicle controls that matter for interpretation.
-
AT-406 in TNBC: Reading Cell Death Beyond Apoptosis
2026-09-27
AT-406 (SM-406) can help researchers interrogate how IAP inhibition reshapes cell-death responses in cancer models. This article examines recent TNBC findings and translates them into a practical framework for distinguishing apoptosis from necroptosis-like and autophagy-associated signals.
-
Risedronate Sodium: Practical Bone and Lung Workflows
2026-09-26
Turn Risedronate Sodium’s FPPS inhibition into practical workflows for osteoclast and pulmonary-delivery studies, with dose-screening, formulation, and troubleshooting guidance. A lung-targeted Risedronate/vitamin D₃ study offers a useful nanoparticle benchmark while also clarifying what remains preclinical.
-
DEBIO 1143 in Murine TNBC: Cell-Death Mechanisms
2026-09-25
This study combines cell-based assays with molecular docking and 1-μs molecular-dynamics simulations to examine DEBIO 1143 in murine breast cancer models. Its findings link cIAP1 depletion with cytotoxicity and increased autophagy-associated and necroptosis-like responses, while cautioning that these changes do not establish direct drug binding to the measured downstream mediators.
-
Angiotensin Peptides Enhance SARS-CoV-2 Spike Binding
2026-09-25
Oliveira and colleagues report that several naturally occurring angiotensin peptides enhance SARS-CoV-2 spike-protein binding to host-cell receptors, with effects that depend on peptide length and sequence. The findings identify a possible biochemical connection between renin–angiotensin system peptides and viral receptor binding, but do not establish that these interactions increase infection in cells or disease in vivo.
-
FOXO3 Blocks Dual Metabolism in HCC
2026-09-24
The study identifies FOXO3 as a tumor suppressor that represses YAP and coordinately limits glycolysis and glutaminolysis in hepatocellular carcinoma. Its cell, in vivo, and patient-derived organoid findings support the FOXO3/YAP axis as a preclinical strategy for disrupting metabolic adaptation, while leaving important questions about clinical translation unresolved.
-
SB525334 (TGF-beta1 receptor inhibitor): Lab Guide
2026-09-24
A practical guide to using SB525334 (TGF-beta1 receptor inhibitor), SKU A5602, to investigate ALK5-dependent signaling in cell-based and renal fibrosis research. Covers assay interpretation, compound handling, evidence from a diabetic wound-healing study, and grounded criteria for selecting a supplier.